PDF(Pubmed)
Abstract：
Background: As delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevailed in the current coronavirus disease 2019 (COVID-19) pandemic, its clinical characteristics with the difference from those of wild-type strains have been little studied. Methods: We reported one cohort of 341 wild-type patients with COVID-19 admitted at Wuhan, China in 2020 and the other cohort of 336 delta variant patients with COVID-19 admitted at Yangzhou, China in 2021, with comparisons of their demographic information, medical history, clinical manifestation, and hematological data. Furthermore, within the delta variant cohort, patients with none, partial, and full vaccination were also compared to assess vaccine effectiveness. Findings: For a total of 677 patients with COVID-19 included in this study, their median age was 53.0 years [interquartile range (IQR): 38.0-66.0] and 46.8% were men. No difference was found in age, gender, and percentage of patients with the leading comorbidity between wild-type and delta variant cohorts, but delta variant cohort showed a lessened time interval between disease onset to hospitalization, a reduced portion of patients with smoking history, and a lowered frequency of clinical symptoms. For hematological parameters, most values demonstrated significant differences between wild-type and delta variant cohorts, while full vaccination rather than partial vaccination alleviated the disease condition. This reflected the viremic effect of delta variant when vaccination succeeds or fails to protect. Interpretation: Delta variant of SARS-CoV-2 may cause severe disease profiles, but timely diagnosis and full vaccination could protect patients with COVID-19 from worsened disease progression.
摘要：
背景：由于严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）的三角洲变体在当前的2019年冠状病毒病（COVID-19）大流行中盛行，其临床特征与野生型菌株的差异研究甚少。方法：我们报告了在武汉收治的341例野生型COVID-19患者的队列，2020年中国和扬州收治的另一批336名三角洲变异COVID-19患者，2021年的中国，以及他们的人口统计信息的比较，病史,临床表现,和血液学数据。此外，在三角洲变异队列中，没有病人，局部,和全面接种疫苗也进行了比较，以评估疫苗的有效性。研究结果：本研究共纳入677例COVID-19患者，他们的中位年龄为53.0岁[四分位距(IQR):38.0-66.0],其中46.8%为男性.在年龄上没有发现差异，性别,以及野生型和delta变异型队列之间具有主要合并症的患者百分比，但是delta变异队列显示疾病发作到住院之间的时间间隔减少，有吸烟史的患者比例减少，降低了临床症状的发生频率.对于血液学参数，大多数值表明野生型和δ变体队列之间存在显着差异，而完全接种疫苗而不是部分接种疫苗缓解了疾病状况。这反映了当疫苗接种成功或未能保护时δ变体的病毒血症效应。解释：SARS-CoV-2的Delta变体可能会导致严重的疾病概况，但及时诊断和全面接种疫苗可以保护COVID-19患者免受恶化的疾病进展。
